Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab plus lenvatinib as neoadjuvant or adjuvant therapy for hepatocellular carcinoma with portal vein non-main trunk tumor thrombus
ChiCTR2400080293Phase 2Not yet recruiting
- Sponsor
- Southwest Hospital of Army Medical University
- Start
- Jan 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of tislelizumab and lenvatinib in hepatocellular carcinoma (HCC) (2 arms), sponsored by Southwest Hospital of Army Medical University. Primary endpoint: 1-year recurrence-free survival rate. Planned start Jan 2024; status: not yet recruiting.
02
Drugs
tislelizumablenvatinib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR2400080293.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400080293.